Long-term outcomes of anti-vascular endothelial growth factor treatment in peripapillary choroidal neovascularisation due to age-related macular degeneration.
Anti-VEGF treatment for peripapillary choroidal neovascularisation was associated with 38% disease inactivity.
Long-term outcomes of anti-vascular endothelial growth factor treatment in peripapillary choroidal neovascularisation due to age-related macular degeneration.
To report the long-term outcomes of anti-vascular endothelial growth factor (VEGF) treatment in eyes with peripapillary choroidal neovascularisation (peripapillary choroidal neovascularisation) associated with age-related macular degeneration (AMD).
A retrospective cohort study included patients with AMD-related peripapillary choroidal neovascularisation.
Best corrected visual acuity (BCVA) remained stable for the first four years of follow up, with a significant deterioration in BCVA thereafter.
Baseline BCVA was a significant predictor of final BCVA (p < 0.001).
Subretinal fluid (subretinal fluid) at presentation was significantly associated with decreased inactivation index (p < 0.05).
Worse baseline BCVA, subretinal fluid and pigment epithelium detachment (pigment epithelium detachment), male sex, and younger patient age were associated with increased risk for recurrence after first inactivation (p < 0.05).
The use of anti-VEGF agents in the treatment of AMD-related peripapillary choroidal neovascularisation managed to preserve BCVA in the first four years of follow-up.
Male sex, subretinal fluid and pigment epithelium detachment at presentation and baseline BCVA are associated with increased risk for peripapillary choroidal neovascularisation recurrence after the first inactivation, and should prompt careful follow-up in these patients.